Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gebasaxturev - Viralytics

Drug Profile

Gebasaxturev - Viralytics

Alternative Names: CAV21; Cavatak; Coxsackievirus A21; CVA 21; V 937

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViroTarg
  • Developer Merck & Co; Viralytics
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action CD55 antigen inhibitors; Cell death stimulants; Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
  • No development reported Bladder cancer; Chronic lymphocytic leukaemia; Glioma; Lung cancer; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Uveal melanoma

Most Recent Events

  • 01 Mar 2024 Merck & Co terminated a phase II trial in Malignant melanoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Australia, Chile, France, Germany, Israel, Italy, Norway, Spain, South Korea, South Africa, New Zealand, the UK, and the US (Intratumoural) (IV) due to business reasons (NCT04152863)
  • 25 Jul 2023 Merck & Co completes a phase I/II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Canada, France, Japan, Israel, Italy, Germany, Hungary, Norway, Peru, Poland, Portugal, Spain, USA, Taiwan (Intratumoural) (EudraCT2020-001908-42) (NCT04521621)
  • 12 Jul 2023 Merck & Co completes a phase-II trial in Malignant melanoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Australia, Chile, France, Germany, Israel, Italy, Norway, Spain, South Korea, South Africa, New Zealand, the UK, and the US (Intratumoural) (IV) (NCT04152863)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top